Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
7.12
0.00 (0.00%)
At close: Mar 18, 2026, 4:00 PM EDT
6.98
-0.14 (-1.97%)
After-hours: Mar 18, 2026, 4:59 PM EDT
Climb Bio Stock Forecast
Stock Price Forecast
The 8 analysts that cover Climb Bio stock have a consensus rating of "Strong Buy" and an average price target of $15.5, which forecasts a 117.70% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $25.
Price Target: $15.5 (+117.70%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Climb Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 4 |
| Buy | 3 | 3 | 3 | 3 | 4 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +138.76% | Mar 18, 2026 |
| Raymond James | Raymond James | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +251.12% | Mar 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $15 | Strong Buy | Maintains | $11 → $15 | +110.67% | Mar 10, 2026 |
| Wedbush | Wedbush | Buy Maintains $12 → $14 | Buy | Maintains | $12 → $14 | +96.63% | Mar 6, 2026 |
| Baird | Baird | Buy Maintains $9 → $12 | Buy | Maintains | $9 → $12 | +68.54% | Mar 6, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.90
from -0.90
EPS Next Year
-1.14
from -0.90
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.76 | -1.10 | |||
| Avg | -0.90 | -1.14 | |||
| Low | -1.06 | -1.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.